Astrana Health, Inc. (ASTH)
| Market Cap | 1.92B +11.5% |
| Revenue (ttm) | 3.84B +58.9% |
| Net Income | 40.55M +60.5% |
| EPS | 0.82 +56.8% |
| Shares Out | 51.17M |
| PE Ratio | 45.80 |
| Forward PE | 22.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 317,047 |
| Open | 35.87 |
| Previous Close | 35.87 |
| Day's Range | 35.87 - 37.70 |
| 52-Week Range | 18.08 - 51.60 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 51.67 (+37.6%) |
| Earnings Date | Nov 5, 2026 |
About ASTH
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients prima... [Read more]
Financial Performance
In 2025, Astrana Health's revenue was $3.18 billion, an increase of 56.39% compared to the previous year's $2.03 billion. Earnings were $22.49 million, a decrease of -47.89%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ASTH stock is "Strong Buy." The 12-month stock price target is $51.67, which is an increase of 37.60% from the latest price.
News
Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call
ALHAMBRA, Calif., Oct. 9, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technolo...
ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ASTH--ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law.
Lowey Dannenberg, P.C. is Investigating Astrana Health, Inc. (NASDAQ: ASTH) for Potential Violations of the Federal Securities Laws
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C.
Astrana Health down 8% after GlassHouse Research short report
10:00 EDT Astrana Health (ASTH) down 8% after GlassHouse Research short report
Astrana Health named as short idea by GlassHouse Research
09:58 EDT Astrana Health (ASTH) named as short idea by GlassHouse Research
GlassHouse Research says short Astrana Health
GlassHouse Research disclosed that the firm is short Astrana Health (ASTH), arguing in a newly-published report that Astrana’s profit “depends on an unusual stack of management estimates – reserves, P...
Oppenheimer bullish on Astrana Health, initiates with an Outperform
As previously reported, Oppenheimer initiated coverage of Astrana Health (ASTH) with an Outperform rating and $53 price target The firm cites the company’s dense market positioning that creates durabl...
Astrana Health initiated with an Outperform at Oppenheimer
Oppenheimer analyst Michael Wiederhorn initiated coverage of Astrana Health (ASTH) with an Outperform rating and $53 price target
Astrana Health Slides: Investor presentation
Astrana Health has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Astrana Health price target raised to $55 from $47 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Astrana Health (ASTH) to $55 from $47 and keeps a Buy rating on the shares. The firm notes that it…
Astrana Health price target raised to $55 from $47 at Truist
Truist raised the firm’s price target on Astrana Health (ASTH) to $55 from $47 and keeps a Buy rating on the shares. Astrana Health’s strong execution, favorable medical cost trends,…
Astrana Health price target raised to $53 from $50 at Barclays
Barclays raised the firm’s price target on Astrana Health (ASTH) to $53 from $50 and keeps an Overweight rating on the shares post the Q2 report. The company’s cost trend…
Astrana Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 49% revenue growth and 43% adjusted EBITDA growth, with strong free cash flow and deleveraging ahead of plan. Full year guidance was raised, driven by robust performance in full risk contracts, successful Prospect integration, and continued investment in growth opportunities.
Astrana Health Earnings release: Q2 2026
Astrana Health released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Astrana Health Slides: Q2 2026
Astrana Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Astrana Health Quarterly report: Q2 2026
Astrana Health has published its Q2 2026 quarterly earnings report on August 6, 2026.
Astrana Health sees 2026 revenue $3.8B-$4.1B, consensus $4.0B
Sees 2026 adjusted EBITDA $255M-$280M.
Astrana Health reports Q2 EPS 80c vs. 55c last year
Reports Q2 revenue $972.5M, consensus $985.33M. “Our Q2 results reflect the strength of Astrana’s physician-centric, AI-native healthcare operating system and the disciplined execution of our team,” s...
Astrana Health sees Q3 revenue $1.0B-$1.03B, consensus $1.02B
Sees Q3 adjusted EBITDA $72.5M-$77.5M.
Astrana Health, Inc. Reports Second Quarter 2026 Results
Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m.
Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call
ALHAMBRA, Calif., July 14, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technol...
Astrana Health price target raised to $50 from $45 at TD Cowen
TD Cowen raised the firm’s price target on Astrana Health (ASTH) to $50 from $45 and keeps a Buy rating on the shares. The firm adjusted targets in the healthcare…
Astrana Health price target raised to $65 from $50 at BTIG
BTIG analyst David Larsen raised the firm’s price target on Astrana Health (ASTH) to $65 from $50 and keeps a Buy rating on the shares. Astrana Health continues to benefit…
Astrana Health Strengthens Leadership Team to Accelerate Long-Term Growth
Names Daniel Rothman President of Physician Enterprise and Vishal Gupta Senior Vice President of Enterprise Transformation ALHAMBRA, Calif., July 13, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astran...
Astrana Health ACOs Deliver $120.4 Million in Gross Shared Savings in 2024 Performance Year
All Eight ACOs Achieve Net Shared Savings ALHAMBRA, Calif., July 13, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (N...